Saturday 28 May 2022
- Advertisement -

Study confirms efficacy of new Ebola vaccine

London: A study published in The Lancet, one of the world’s oldest and best known medical journals, found the rVSV-ZEVOB ebola vaccine can provide up to 100% protection against onset of Zaire ebolavirus, one of the 2 most common strains of Ebola, responsible for most of the cases observed in humans. Iowa-based NewLink Genetics, which owns the rights to rVSV-ZEVOB, on Friday announced hope the US Food and Drug Administration (FDA) would award them a priority review voucher in recognition of their work with the vaccine.

The Zaire ebolavirus is considered to be the most dangerous of the 5 of Ebola virus that have been identified.

The study’s findings also show the vaccine is effective post-exposure, which makes it suitable for ring vaccination, the anti- strategy used in the study, in which everyone who has come into contact with a confirmed case is vaccinated to prevent the illness from spreading.

NewLink’s chief scientific officer for infectious diseases, Thomas Monath, said the FDA would likely approve the vaccine quickly, with large-scale production as early as 2018.

This might not be the only NewLink project to be waved to the front of the line. Priority review vouchers are awarded by the FDA as a means of providing an incentive for private industry to focus on tropical diseases and rare conditions. Any company that sees an eligible vaccine or treatment formally licensed can receive a voucher for fast-track FDA review on a future project. They can either keep the voucher for their own use or sell it. According to Monath, they can sell for $100–300 million, and NewLink would share the money from any such sale with Merck, which currently holds the license on the vaccine.

rVSV-ZEVOB was initially developed by the Public Health Agency of Canada and the United States Army. It is a recombinant live replication-competent virus based on vesicular stomatitis virus. Although it is harmless to humans, it has been engineered to express one of the same surface marker proteins as the Zaire ebolavirus, which trains the host’s immune system to recognize both the vaccine and the true virus.

US President added Ebola to the priority review voucher program in December 2014 during the outbreak in West Africa.

From Wikinews under Creative Commons Attribution 2.5 licence

Contribute to our cause

Contribute to the nation's cause

Sirf News needs to recruit journalists in large numbers to increase the volume of its reports and articles to at least 100 a day, which will make us mainstream, which is necessary to challenge the anti-India discourse by established media houses. Besides there are monthly liabilities like the subscription fees of news agencies, the cost of a dedicated server, office maintenance, marketing expenses, etc. Donation is our only source of income. Please serve the cause of the nation by donating generously.

Join Sirf News on


Similar Articles


Scan to donate

Swadharma QR Code
Sirf News Facebook Page QR Code
Facebook page of Sirf News: Scan to like and follow

Most Popular

%d bloggers like this: